MAILLARD REACTION INHIBITOR CONSISTING MAINLY OF 3-OXYGERMYLPROPIONIC ACID COMPOUND

PURPOSE: To obtain a Maillard reaction inhibitor having excellent Maillard reaction inhibitory activity, thus useful as a therapeutic agent for diabetes and diabetic complications caused by Maillard reaction, containing, as the chief ingredient, a 3-oxygermylpropionic acid 8-membered polymer. CONSTI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ISHIWATARI YOSHIRO, SAWAI KIICHI, NINOMIYA NAOHISA, MITANI TAKAHIKO
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PURPOSE: To obtain a Maillard reaction inhibitor having excellent Maillard reaction inhibitory activity, thus useful as a therapeutic agent for diabetes and diabetic complications caused by Maillard reaction, containing, as the chief ingredient, a 3-oxygermylpropionic acid 8-membered polymer. CONSTITUTION: This Maillard reaction inhibitor contains, as the chief ingredient, a 3-oxygermylpropionic acid 8-membered polymer of the formula (R is CH2 CH2 COOH; (m) is the weight-average polymerization degree reduced from the weight-average molecular weight of propagermanium propyl ester, being 137±84) with the minimum constituent unit of (01/2 )3 GeCH2 CH2 COOH and the experimental formula of C6 H10 Ge2 O7 , It is preferable that the dose of this inhibitor be 1-1500mg and 150mg/day for the oral administratior for an adult with a body weight of 50 kg.